Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer
Interventions: DRUG: Adavosertib|DRUG: Afatinib|DRUG: Afatinib Dimaleate|DRUG: Binimetinib|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|DRUG: Capivasertib|PROCEDURE: Computed Tomography|DRUG: Copanlisib|DRUG: Copanlisib Hydrochloride|DRUG: Crizotinib|OTHER: Cytology Specimen Collection Procedure|DRUG: Dabrafenib|DRUG: Dabrafenib Mesylate|DRUG: Dasatinib|DRUG: Defactinib|DRUG: Defactinib Hydrochloride|PROCEDURE: Echocardiography|DRUG: Erdafitinib|DRUG: Fexagratinib|DRUG: Ipatasertib|OTHER: Laboratory Biomarker Analysis|DRUG: Larotrectinib|DRUG: Larotrectinib Sulfate|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|DRUG: Osimertinib|DRUG: Palbociclib|BIOLOGICAL: Pertuzumab|DRUG: PI3K-beta Inhibitor GSK2636771|PROCEDURE: Radiologic Examination|BIOLOGICAL: Relatlimab|DRUG: Sapanisertib|DRUG: Sunitinib Malate|DRUG: Taselisib|DRUG: Trametinib|BIOLOGICAL: Trastuzumab|BIOLOGICAL: Trastuzumab Emtansine|DRUG: Ulixertinib|DRUG: Vismodegib
Sponsor: National Cancer Institute (NCI)